Abstract
Protease inhibitors (PIs) inhibit the cytochrome P450 CYP3A4 [1]. Because the metabolism of pravastatin is independent of the cytochrome P450 CYP3A4, this drug has become the preferred statin for treatment of dyslipidemia associated with human immunodeficiency virus (HIV) infection, with no cases of serious toxicity such as rhabdomyolysis reported to date. We report an HIV-infected patient receiving antiretroviral regimen consisting of atazanavir, ritonavir, emtricitabine and tenofovir who developed severe rhabdomyolysis approximately 4 months after increasing his pravastatin dose from 40 to 80 mg daily. His symptoms resolved within 10 days after the discontinuation of pravastatin and antiretroviral therapy. To our knowledge, this is the first case of rhabdomyolysis possibly caused by pravastatin in an HIV-infected patient.
Current Drug Safety
Title: Rhabdomyolysis in an HIV-Infected Patient on Anti-Retroviral Therapy Precipitated by High-Dose Pravastatin
Volume: 4 Issue: 2
Author(s): Nasser Mikhail, Elizabeth Iskander and Dennis Cope
Affiliation:
Abstract: Protease inhibitors (PIs) inhibit the cytochrome P450 CYP3A4 [1]. Because the metabolism of pravastatin is independent of the cytochrome P450 CYP3A4, this drug has become the preferred statin for treatment of dyslipidemia associated with human immunodeficiency virus (HIV) infection, with no cases of serious toxicity such as rhabdomyolysis reported to date. We report an HIV-infected patient receiving antiretroviral regimen consisting of atazanavir, ritonavir, emtricitabine and tenofovir who developed severe rhabdomyolysis approximately 4 months after increasing his pravastatin dose from 40 to 80 mg daily. His symptoms resolved within 10 days after the discontinuation of pravastatin and antiretroviral therapy. To our knowledge, this is the first case of rhabdomyolysis possibly caused by pravastatin in an HIV-infected patient.
Export Options
About this article
Cite this article as:
Mikhail Nasser, Iskander Elizabeth and Cope Dennis, Rhabdomyolysis in an HIV-Infected Patient on Anti-Retroviral Therapy Precipitated by High-Dose Pravastatin, Current Drug Safety 2009; 4 (2) . https://dx.doi.org/10.2174/157488609788173080
DOI https://dx.doi.org/10.2174/157488609788173080 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obesity and Gestational Diabetes in Pregnant Care and Clinical Practice
Current Vascular Pharmacology Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued) Extracellular Vesicles Isolated from Mesenchymal Stromal Cells Primed with Hypoxia: Novel Strategy in Regenerative Medicine
Current Stem Cell Research & Therapy Immunotherapy in a Rabbit Model of Alzheimer’s Disease
Drug Delivery Letters Antithrombotic Therapy in Lower Extremity Artery Disease
Current Vascular Pharmacology Hypertensive Disorders in Pregnancy Current Practice Review
Current Hypertension Reviews Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) [1, 2, 4]-Oxadiazoles: Synthesis and Biological Applications
Mini-Reviews in Medicinal Chemistry Mouse Models and the Role of Nitric Oxide in Reproduction
Current Pharmaceutical Design Novel Concepts in the Pathogenesis and Management of Pediatric Hypertension
Current Pediatric Reviews Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets The Role and Significance of Unconventional Hydrogen Bonds in Small Molecule Recognition by Biological Receptors of Pharmaceutical Relevance
Current Pharmaceutical Design Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review
Cardiovascular & Hematological Disorders-Drug Targets Sympathetic Nervous System in Patients with Sleep Related Breathing Disorders
Current Hypertension Reviews Antipsychotic Drugs and Cerebrovascular Events in Elderly Patients with Dementia: A Systematic Review
Mini-Reviews in Medicinal Chemistry Patent Selections :
Recent Patents on Cardiovascular Drug Discovery Blood Pressure Management in Metabolic Syndrome
Current Hypertension Reviews Arterial Stiffness and Cardiovascular Drugs
Current Pharmaceutical Design Thienopyridines and Statins: Assessing a Potential Drug-Drug Interaction
Current Pharmaceutical Design New Thrombin and Factor Xa Inhibitors for Primary and Secondary Prevention of Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets